

NEKTAR THERAPEUTICS  
Form SD  
May 15, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM SD**

**Specialized Disclosure Report**

**NEKTAR THERAPEUTICS**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b> <b>(State or other jurisdiction of</b>	<b>0-24006</b> <b>(Commission</b>	<b>94-3134940</b> <b>(IRS Employer</b>
<b>incorporation or organization)</b>	<b>File Number)</b>	<b>Identification No.)</b>

**455 Mission Bay Boulevard South**

**San Francisco, California**  
**(Address of principal executive offices)**

**Mark A. Wilson**

**94158**  
**(Zip Code)**

Edgar Filing: NEKTAR THERAPEUTICS - Form SD

**Vice President and General Counsel**

**(415) 482-5300**

**(Name and telephone number, including area code, of the person to contact in connection with this report.)**

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in the form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2015 to December 31, 2016.

**Section 1 Conflict Minerals Disclosure**

**Item 1.01 Conflict Minerals Disclosure and Report**

This Form SD is filed by Nektar Therapeutics (the Company ) pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2015 to December 31, 2016.

A copy of the Company s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD, and is publicly available on the Company s website at [www.nektar.com](http://www.nektar.com) under the heading Investors within the Financials & Filings tab.

**Item 1.02 Exhibit**

The Conflict Minerals Report required by Items 1.01 and 1.02 is filed as Exhibit 1.01 to this Form SD.

**Section 2 Exhibits**

**Item 2.01 Exhibits**

Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**NEKTAR THERAPEUTICS**

Date: May 15, 2017

/s/ Mark A. Wilson  
Mark A. Wilson  
Vice President and General Counsel